Quantcast

Latest Novogen Limited Stories

2014-08-12 08:30:36

SYDNEY, Aug. 12, 2014 /PRNewswire/ -- The Australian biotechnology company, Novogen Limited (ASX: NRT; NASDAQ: NVGN), today announced receipt of funding from the FSHD Global Research Foundation as part of the Company's efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD). http://photos.prnewswire.com/prnvar/20131220/NY36990LOGO FSHD is one of the most common forms of muscular dystrophy and genetic hereditary...

2014-06-17 08:28:31

Companies expect to commence first-in-human studies of Trx-1 in ovarian cancer in 1H15 BOSTON, June 17, 2014 /PRNewswire/ -- Australian oncology drug development company Novogen Limited [ASX:NRT; NASDAQ:NVGN] and CanTx Inc., its joint venture with Yale University, today announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity. Based on the...

2014-05-27 08:27:52

SYDNEY, May 27, 2014 /PRNewswire/ -- Novogen Limited (NASDAQ: NVGN, ASX:NRT), an oncology drug development company, today announced that it has achieved a key milestone with its super-benzopyran (SBP) drug program, having identified a number of SBP compounds with potent anti-cancer activity against human prostate cancer cells in vitro. As a result, Novogen has extended its preclinical SBP program to include prostate cancer as well as ovarian and brain cancers....

2014-05-02 12:26:34

SYDNEY, May 2, 2014 /PRNewswire/ -- Novogen Limited (NASDAQ: NVGN, ASX: NRT;), an oncology drug development company, today announced a collaboration with Australian company, Genea Biocells, to accelerate testing of their super-benzopyran (SBP) drugs for degenerative diseases of the nervous system and muscles. http://photos.prnewswire.com/prnvar/20131220/NY36990LOGO Preliminary research conducted by both companies found that super-benzopyrans appear to be effective at promoting the...

2014-03-18 08:32:17

Experimental drug designed to fight abdominal cancers passes important test SYDNEY, March 18, 2014 /PRNewswire/ -- Novogen Limited [ASX:NRT; NASDAQ:NVGN] and its joint venture company with Yale University, CanTx Inc, today announced an important milestone with lead candidate drug, Trx-1, demonstrating a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cells. http://photos.prnewswire.com/prnvar/20131220/NY36990LOGO CanTx is seeking a novel approach to...

2014-03-12 12:28:56

SYDNEY, March 12, 2014 /PRNewswire/ -- Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced that Graham Kelly, Ph.D., Executive Director and Chief Executive Officer, will present at the 2(nd) Annual Sachs Cancer Bio Partnering & Investment Forum. Dr. Kelly's presentation will take place at 2:30 p.m. on Wednesday, March 19, 2014 at the New York Academy of Sciences in New York City....

2014-03-10 16:31:37

Forum uniquely brings together leading family offices and their foundations seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences SYDNEY, March 10, 2014 /PRNewswire/ -- Novogen Limited (ASX: 'NRT'; NASDAQ: 'NVGN'), an oncology drug development company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 at the United Nations Headquarters in New York. The purpose of the...

2014-03-04 08:30:57

SYDNEY, March 4, 2014 /PRNewswire/ -- Novogen Limited (ASX:NRT; NASDAQ:NVGN]), an oncology drug development company, today announced key new appointments to guide the company in its transition into a clinical-stage company with a growing U.S. presence and an investor base in the U.S. and Australia. Professor Peter Gunning, PhD, a leading world authority on the cytoskeleton, and Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive, join the Novogen board...

2014-02-03 12:29:37

Co-inventors of ATM technology joining company as General Manager of the ATM Program, Scientific Advisory Panel member, respectively SYDNEY, Feb. 3, 2014 /PRNewswire/ -- Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced the appointments of Justine Stehn, PhD and Professor Peter Gunning, PhD to roles within the Company. Dr. Stehn and Professor Gunning are the co-inventors of the anti-tropomyosin (ATM) drug technology platform that Novogen...

2014-01-30 20:23:07

Event to take place on Friday, February 7, 2014 at 8:00 a.m. (Sydney local time), Thursday, February 6, 2014 at 4 p.m. ET SYDNEY, Jan. 30, 2014 /PRNewswire/ -- Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced it will host a corporate update with Graham Kelly, Ph.D., Novogen Group Executive Chairman and Chief Executive Officer, and David Brown, Ph.D., Chief Scientific Officer on Friday, February 7, 2014 at 8:00 a.m. (Sydney local time)....


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related